Respiratory and miotic effects of morphine in healthy volunteers when P‐glycoprotein is blocked by quinidine

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Clinical pharmacology and therapy

• Publication date

  2003-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0009-9236(03)00220-0PMID 14534517
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of morphine are not altered in subjects with Gilbert's syndrome.

  2003cited by this paper
• Applied Multivariate Statistics for the Social Sciences

  2003cited by this paper
• Analgesic effects of morphine and morphine‐6‐glucuronide in a transcutaneous electrical pain model in healthy volunteers

  2003cited by this paper
• Interaction of Morphine, Fentanyl, Sufentanil, Alfentanil, and Loperamide with the Efflux Drug Transporter P-glycoprotein

  2002cited by this paper
• The influence of P-glycoprotein on morphine transport in Caco-2 cells. Comparison with paclitaxel.

  2002cited by this paper
• Pharmacokinetic modeling to predict morphine and morphine‐6‐glucuronide plasma concentrations in healthy young volunteers

  2002cited by this paper
• Increased CNS uptake and enhanced antinociception of morphine‐6‐glucuronide in rats after inhibition of P‐glycoprotein

  2002cited by this paper
• The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology

  2001cited by this paper
• Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs

  2001cited by this paper
• The Transfer Half-life of Morphine-6-glucuronide from Plasma to Effect Site Assessed by Pupil Size Measurement in Healthy Volunteers

  2001cited by this paper
• Effect of mdr1a P-Glycoprotein Gene Disruption, Gender, and Substrate Concentration on Brain Uptake of Selected Compounds

  2001cited by this paper
• Screening of Multidrug-Resistance Sensitive Drugs by In Situ Brain Perfusion in P-Glycoprotein-Deficient Mice

  2001cited by this paper
• Opiate-induced Analgesia Is Increased and Prolonged in Mice Lacking P-glycoprotein

  2000cited by this paper
• Morphine Antinociception Is Enhanced in mdr1a Gene-Deficient Mice

  2000cited by this paper
• Increased drug delivery to the brain by P‐glycoprotein inhibition

  2000cited by this paper
• Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine.

  2000cited by this paper
• The role of P‐glycoprotein in blood‐brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (−/−) and mdr1a (+/+) mice

  1999cited by this paper
• Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat.

  1999cited by this paper
• Modulation of morphine-6-glucuronide penetration into the brain by P-glycoprotein.

  1998cited by this paper
• AN ANALYSIS OF THE TIME‐RELATIONS OF ELECTROCARDIOGRAMS.

  1997cited by this paper
• Evidence for P‐glycoprotein‐modulated penetration of morphine‐6‐glucuronide into brain capillary endothelium

  1996cited by this paper
• Applied Multivariate Statistics for the Social Sciences

  1993cited by this paper
• Morphine‐6‐glucuronide: effects on ventilation in normal volunteers

  1991cited by this paper
• Regulation of ventilation during rebreathing at imposed respiratory frequencies.

  1966cited by this paper

• Metabolite-centric perspectives on QT prolongation: molecular mechanisms and clinical implications beyond the parent drug.

  2025cites this paper
• Do P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier impact morphine brain distribution?

  2025cites this paper
• PBPK-PD model for predicting morphine pharmacokinetics, CNS effects and naloxone antagonism in humans

  2024influential citation
• "3,3-Dibromoflavanone, a Synthetic Flavonoid Derivative for Pain Management with Antidepressant-Like Effects and Fewer Side Effects than those of Morphine in Mice".

  2024cites this paper
• Extended-release and long-acting opioids for chronic pain management.

  2023cites this paper
• Pharmacological data science perspective on fatal incidents of morphine treatment.

  2022cites this paper
• Codeine , morphine , and metformin : Common aspects of drug transport , drug-drug interactions , and pharmacogenetics

  2021cites this paper
• Management of Acute Postoperative Pain in the Geriatric Patient

  2020cites this paper
• The Impact of Opioid Analgesics and the Pharmacogenomics of ABCB1 in Opioid Dependence and Pharmacotherapies: A Short Review

  2020cites this paper
• Pharmakologische Grundlagen: Mechanismen und Variabilität der Wirkung psychoaktiver Substanzen

  2018cites this paper
• The Pharmacology of Intravenous Opioids

  2018cites this paper
• Pharmacogenetics of opioid analgesics in dogs

  2018cites this paper
• Opioids and the Blood-Brain Barrier: A Dynamic Interaction with 
Consequences on Drug Disposition in Brain

  2017cites this paper
• Objective methods for the assessment of the spinal and supraspinal effects of opioids

  2017cites this paper
• Clinical Implications of P-Glycoprotein Modulation in Drug–Drug Interactions

  2017cites this paper
• 38 : Opioids

  2016cites this paper
• Pharmacogenetics of Opioid Therapy in Treatment of Postoperative Pain: A Review

  2016cites this paper
• Reply to: Letter to the Editor “Effect of Quinidine, a Strong P‐Glycoprotein Inhibitor, on the Pharmacokinetics and Central Nervous System Distribution of Naloxegol”

  2016cites this paper
• [Role of Scaffold Proteins in Functional Alteration of Small Intestinal P-glycoprotein by Anti-cancer Drugs].

  2015cites this paper
• Mechanisms of P-glycoprotein alteration during anticancer treatment: role in the pharmacokinetic and pharmacological effects of various substrate drugs.

  2014cites this paper
• 抗がん剤治療時における P-glycoproteinの発現・機能変動と薬物動態並びに薬理作用へ及ぼす影響

  2014cites this paper
• Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers.

  2014cites this paper
• New insights into enhancing morphine analgesia: from glia to pharmacokinetics

  2014cites this paper
• The mineralocorticoid receptor antagonist spironolactone enhances morphine antinociception

  2014cites this paper
• Why Clinical Modulation of Efflux Transport at the Human Blood–Brain Barrier Is Unlikely: The ITC Evidence‐Based Position

  2013cites this paper
• Cyclosporine-inhibitable Blood–Brain Barrier Drug Transport Influences Clinical Morphine Pharmacodynamics

  2013cites this paper
• Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood–brain barrier in mice

  2012cites this paper
• Psychotropic Drug–Drug Interactions Involving P-Glycoprotein

  2012cites this paper
• Non-analgesic effects of opioids: interactions between opioids and other drugs.

  2012cites this paper
• Acute Postoperative Pain Management in Elderly Patients

  2011cites this paper
• OPRM1 gene variants modulate amphetamine‐induced euphoria in humans

  2011cites this paper
• Chapter 106 – Toxidromes and Their Treatment

  2011cites this paper
• Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance.

  2011cites this paper
• General Anaesthesia in Elderly Patients with Cardiovascular Disorders

  2010cites this paper
• Selective Antagonism of Opioid‐Induced Ventilatory Depression by an Ampakine Molecule in Humans Without Loss of Opioid Analgesia

  2010cites this paper
• Meta‐analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment

  2009cites this paper
• Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers

  2009cites this paper
• A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs.

  2008cites this paper
• Variations in opioid responsiveness.

  2008cites this paper
• Effects of ketoconazole on the pharmacokinetics and pharmacodynamics of morphine in healthy Greyhounds.

  2008cites this paper
• Tariquidar, a Selective P-glycoprotein Inhibitor, Does Not Potentiate Loperamide’s Opioid Brain Effects in Humans despite Full Inhibition of Lymphocyte P-glycoprotein

  2008cites this paper
• Itraconazole, a potent inhibitor of P‐glycoprotein, moderately increases plasma concentrations of oral morphine

  2008cites this paper
• Pharmacogenetics of analgesics: toward the individualization of prescription.

  2008cites this paper
• The Pharmacology of Opioids

  2008cites this paper
• Pharmacogenetics of Opioids

  2007cites this paper
• 15 Pharmacology of Opioids

  2007cites this paper
• The Partial 5‐Hydroxytryptamine1A Receptor Agonist Buspirone does not Antagonize Morphine‐induced Respiratory Depression in Humans

  2007cites this paper
• Genetic variants of the P-glycoprotein gene Abcb1b modulate opioid-induced hyperalgesia, tolerance and dependence

  2006cites this paper
• Relevance of frequent μ-opioid receptor polymorphisms for opioid activity in healthy volunteers

  2006cites this paper
• Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature.

  2006cites this paper
• Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action

  2006cites this paper
• Individualizing analgesic prescription Part I: pharmacogenetics of opioid analgesics.

  2006cites this paper
• Wirkungsverstärkung oder -reduktion - Arzneimittelinteraktionen in der Schmerztherapie

  2006cites this paper
• Morphine‐6‐glucuronide: Actions and mechanisms

  2005cites this paper
• Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects

  2005cites this paper
• THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL

  2005cites this paper
• Regional Anesthesia and Pain Polymorphisme génétique et interactions médica- menteuses : leur importance dans le traitement de la douleur (Genetic polymorphism and drug interactions: their importance in the treatment

  2005cites this paper
• The 5‐hydroxytryptamine 4 receptor agonist mosapride does not antagonize morphine‐induced respiratory depression

  2005cites this paper
• [Genetic polymorphism and drug interactions: their importance in the treatment of pain].

  2005cites this paper
• Ventilatory responses of healthy subjects to intravenous combinations of morphine and oxycodone under imposed hypercapnic and hypoxaemic conditions.

  2005cites this paper
• Drug Interactions during Anti-Infective Treatments

  2005cites this paper
• Polymorphisme génétique et interactions médicamenteuses : leur importance dans le traitement de la douleur

  2005cites this paper
• Genetic variability and clinical efficacy of morphine

  2005cites this paper
• Primary prevention with over‐the‐counter statins: A cautionary tale

  2005cites this paper
• Probenecid Interacts with the Pharmacokinetics of Morphine-6-glucuronide in Humans

  2004cites this paper
• Quel rôle pour la glycoprotéine-P dans l’activité analgésique des opioïdes?

  2004cites this paper
• Genetyka a opioidy. Nowe dane pozwalające na lepsze zrozumienie analgezji opioidowej

  2004cites this paper
• Endogenous opiates and behavior: 2003.

  2004cites this paper
• Author index

  2003cites this paper